消木丹颗粒对非酒精性脂肪肝大鼠FXR、ApoM表达的影响
Effects of Xiaomudan Granules on the Expressions of FXR and ApoM in Rats with Non-Alcoholic Fatty Liver Disease
-
摘要: 目的 探讨消木丹颗粒对非酒精性脂肪肝(NAFLD)模型大鼠的治疗作用,并探讨其对FXR/ApoM表达的影响。方法 60只SD大鼠按体质量分为正常组,模型组,消木丹颗粒低、中、高剂量组,多烯磷脂酰胆碱组,除正常组外,其余50只采用高脂膳食喂养12周建立NAFLD大鼠模型,造模成功后灌胃给予相应药物,给药4周后取血清及肝脏组织样本。称取大鼠体质量及肝湿质量,计算肝脏指数;HE染色、油红O染色观察肝脏病理变化;ELISA法检测血脂及肝功能水平;免疫组化观察肝组织FXR、ApoM的表达;qPCR法检测肝组织FXR、ApoM mRNA表达水平,Western blot法检测肝脏上述各项基因的蛋白表达。结果 与模型组比较,消木丹颗粒干预后能显著改善NAFLD大鼠体质量、肝脏指数,降低血清ALT、AST、TC、TG、LDL-C含量,增高HDL-C含量,同时能增强肝脏FXR、ApoM的表达,差异有统计学意义(P<0.05~0.01)。结论 消木丹颗粒可调节NAFLD大鼠肝脏的脂质代谢,改善脂质沉积,其机制可能与调控FXR及其相关基因ApoM有关。Abstract: OBJECTIVE To investigate the therapeutic effect of Xiaomudan Granule in rats with non-alcoholic fatty liver (NAFLD) and to observe the effect of Xiaomudan Granule on the expression of Farnesoid X receptor (FXR) and apolipoprotein M (ApoM), and to explore its mechanism. METHODS A total of 60 SD rats were divided into normal group, model group, Xiaomudan Granule treatment groups (low, middle and high treatment group), polyene phosphatidylcholine group according to body weight. Except the normal group, the remaining 50 rats were treated with high fat diet for 12 weeks to induce NAFLD rat model. After the success of the model, the corresponding drugs were given by i.g. administration. Serum lipids and liver tissue were taken after 4-week of administration. Body mass and liver wet weight of rats were measured and liver index was calculated. HE and Oil Red O staining were used to observe the pathological changes of liver tissue. Serum lipids and liver function were detected by ELISA. The expression levels of FXR and ApoM in liver tissues were observed by immunohistochemistry, the mRNA expression levels of FXR and ApoM in liver tissues were detected by qPCR technology. The protein expression levels of the above-mentioned genes in liver were detected by Western blot. RESULTS After the intervention of Xiaomudan Granule, the levels of ALT, AST, TC, TG and LDL-C were significantly reduced and HDL-C was increased. The mRNA expressions of FXR and ApoM in the liver were enhanced, compared with the model group (P<0.05, P<0.01). CONCLUSION Xiaomudan Granule can regulate lipid metabolism and improve lipid deposition in NAFLD rat liver, and the mechanism may be related to the regulation of FXR and its related gene ApoM.
-
Key words:
- Xiaomudan Granule /
- non-alcoholic fatty liver disease /
- FXR /
- ApoM /
- lipid metabolism
-
[1] TRAUSSNIGG S,KIENBACHER C,HALILBASIC E,et al.Challenges and management of liver cirrhosis:Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH[J].Dig Dis,2015,33(4):598-607. [2] KWOK R,TSE YK,WONG GL,et al.Systematic review with meta-analysis:Non-invasive assessment of non-alcoholic fatty liver disease:the role of transient elastography and plasma cytokeratin-18 fragments[J].Aliment Pharmacol Ther,2014,39(3):254-269. [3] WONG RJ, CHEUNG R, AHMED A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S[J]. Hepatology, 2014,59(6):2188-2195. [4] LINDOR KD.Farnesoid X receptor agonists for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2011,27(3):285-288. [5] 黄倩,李京涛,魏海梁,等. 法尼醇受体对非酒精性脂肪性肝病作用研究进展[J]. 中国肝脏病杂志(电子版),2019,11(3):21-25. [6] 任坤,唐振丽,易光辉.载脂蛋白M[J].中国生物化学与分子生物学报,2015,31(6):557-565. [7] 张艳,刘红,彭家和,等.激活类法尼醇X核内受体(FXR)可下调载脂蛋白M在HepG2细胞中的表达[J].中国生物化学与分子生物学报,2009,25(11):1030-1034. [8] ZHU C, DI D, ZHANG X, et al. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells[J]. Lipids Health Dis,2011,10: 199. [9] 刘亚珠,李京涛,席奇.消木丹颗粒治疗非酒精性脂肪性肝病气郁痰阻证临床观察[J].北京中医药,2016,35(3):214-217. [10] 刘宝咸,席奇,南然,等.综合护理干预联合消木丹颗粒治疗30例单纯性脂肪肝疗效观察[J].现代中医药,2016,36(5):22-24. [11] 焦俊喆,关茜,王轲,等.消木丹颗粒联合恩替卡韦治疗慢性乙型病毒性肝炎合并非酒精性脂肪肝临床研究[J].四川中医,2018,36(9):80-83. [12] 吕宝伟,冯春青,孙建光.补肾降浊饮对非酒精性脂肪肝大鼠胰岛素抵抗的影响[J].中国实验方剂学杂志,2018,24(12):107-113. [13] 陈奇.中药药理研究方法学[M].2版.北京:人民卫生出版社,2006:28. [14] XU JS,LI YY,CHEN WD,et al.Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis[J].Hepatology,2014,59(5):1761-1771. [15] REN K,TANG ZL,JIANG Y,et al.Apolipoprotein M[J].Clin Chim Acta,2015,446:21-29. [16] 左小炫. ApoM基因在非酒精性脂肪性肝病形成中的作用[D].芜湖:皖南医学院,2018. [17] 丁静,张斌,王培劼,等.基于数据挖掘和生物信息分析探讨非酒精性脂肪肝用药规律及作用机制[J].中国中药杂志,2019,44(8):1689-1695. [18] 宋保兰.陈皮药理作用[J].实用中医内科杂志,2014,28(8):132-133,160. [19] 邢增智,陈旺,曾宇.泽泻的化学成分与药理作用研究进展[J].中医药导报,2017,23(15):75-78. [20] 董晓强,尹占芳.决明子的化学成分及药理作用研究[J].中国当代医药,2013,20(7):18-19,23. [21] 吴鹏波,宋琪,俞媛洁,等. 姜黄素对非酒精性脂肪肝细胞模型保护作用以及机制研究[J]. 实用肝脏病杂志,2020,23(3):324-327. [22] 梁学清,李丹丹,黄忠威.茯苓药理作用研究进展[J].河南科技大学学报(医学版),2012,30(2):154-156. [23] ZHU CH,DI DM,ZHANG XY,et al.TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells[J].Lipids Health Dis,2011,10:199.
点击查看大图
计量
- 文章访问数: 586
- HTML全文浏览量: 10
- PDF下载量: 484
- 被引次数: 0